有机阴离子转运多肽1B1对2型糖尿病药物治疗的影响

发布时间：2019-07-21 11:58

【摘要】：目的:了解有机阴离子转运多肽1B1(OATP1B1)对2型糖尿病药物治疗的影响。方法:查阅近年来国内外相关文献,就OATP1B1的影响机制、对那格列奈和瑞格列奈等药物的影响、其他基因组信息进行归纳和总结。结果:OATP1B1对那格列奈和瑞格列奈的体内过程影响明显,人类OATP1B1编码基因(SLCO1B1)521TC位点的突变对那格列奈药动学和药效学的影响与野生型对照组比较,差异有统计学意义;OATP1B1对瑞格列奈药动学影响呈剂量依赖关系。SLCO1B1 388AG位点的突变对2型糖尿病药物的体内过程影响不明显。结论:OATP1B1作为摄入型转运体在糖尿病的药物治疗中起重要作用。患者的基因组信息将成为2型糖尿病患者临床合理用药的重要参考因素,有必要对OATP1B1进行更深入、系统的研究。
[Abstract]:Objective: to investigate the effect of organic anion transport polypeptide 1B1 (OATP1B1) on drug therapy of type 2 diabetes mellitus (T2DM). Methods: the influence mechanism of OATP1B1, the influence of nateglinide and repaglinide and other genomic information on nateglinide and repaglinide were summarized by reviewing the relevant literature at home and abroad in recent years. Results: the effect of OATP1B1 on the in vivo process of nateglinide and repaglinide was obvious. The effect of mutation of human OATP1B1 coding gene (SLCO1B1) 521TC site on the pharmacokinetics and pharmacokinetics of nateglinide was significantly different from that of wild type control group. The effect of OATP1B1 on the pharmacokinetics of repaglinide was dose-dependent. The mutation of SLCO1B1 388AG site had no significant effect on the in vivo process of type 2 diabetic drugs. Conclusion: OATP1B1, as an ingestion transporter, plays an important role in the drug treatment of diabetes mellitus. The genomic information of patients will become an important reference factor for clinical rational drug use in patients with type 2 diabetes mellitus. It is necessary to study OATP1B1 more deeply and systematically.
【作者单位】： 皖南医学院附属弋矶山医院临床药学部;
【基金】：国家自然科学基金资助项目(No.81173134)
【分类号】：R587.1
，

本文编号：2517162